<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03019276</url>
  </required_header>
  <id_info>
    <org_study_id>TQ-B3101-1-0001</org_study_id>
    <nct_id>NCT03019276</nct_id>
  </id_info>
  <brief_title>A Phase I Study of TQ-B3101 on Tolerance and Pharmacokinetics</brief_title>
  <official_title>Phase I Study of Tolerance and Pharmacokinetics of TQ-B3101 in Patients With Advanced Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Jiangsu Chia-tai Tianqing Pharmaceutical Co.,Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To study the pharmacokinetic characteristics of TQ-B3101 in the human body, recommend a
      reasonable regimen for subsequent research.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      single arm, single or repeat dosing of TQ-B3101 on patients with solid tumors.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 5, 2017</start_date>
  <completion_date type="Anticipated">December 2018</completion_date>
  <primary_completion_date type="Anticipated">December 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) of TQ-B3101</measure>
    <time_frame>48 weeks</time_frame>
    <description>The highest dose at which no more than 33% of the subjects experience a dose-limiting toxicity (DLT) during treatment</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The type of dose-limiting toxicity(ies) (DLT[s]) of TQ-B3101</measure>
    <time_frame>For 4 weeks for DLTs</time_frame>
    <description>Subjects within 28 days after treatment appear the following toxicity reaction relate to the drug ：III °or above of non-hematological toxicity,IV°hematological toxicity ,Neutropenia associated with fever</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of TQ-B3101 (in whole blood):Peak Plasma Concentration(Cmax)</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Peak Plasma Concentration(Cmax),Cmax in ng/mL.In the study of single-dose, full PK profiles will be obtained at H-24/H-12/H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H36/H48/H72/H96/H120/H144（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D8/D15/D21/D28（D means Day）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of TQ-B3101 (in whole blood):Peak time（Tmax）</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Peak time（Tmax）,Tmax in h.In the study of single-dose, full PK profiles will be obtained at H-24/H-12/H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H36/H48/H72/H96/H120/H144（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D8/D15/D21/D28（D means Day）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of TQ-B3101 (in whole blood):Half life（t1/2）</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Half life（t1/2）,t1/2 in h.In the study of single-dose, full PK profiles will be obtained at H-24/H-12/H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H36/H48/H72/H96/H120/H144（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D8/D15/D21/D28（D means Day）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of TQ-B3101 (in whole blood):Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Area under the plasma concentration versus time curve (AUC), AUC in ng.h/mL.In the study of single-dose, full PK profiles will be obtained at H-24/H-12/H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H36/H48/H72/H96/H120/H144（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D8/D15/D21/D28（D means Day）</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetics of TQ-B3101 (in whole blood):Clearance（CL）</measure>
    <time_frame>up to 28 Days (endpoint when the two consecutive time points of blood drug concentration &lt;150 DPM/mL)</time_frame>
    <description>Clearance（CL）,CL in L/h.In the study of single-dose, full PK profiles will be obtained at H-24/H-12/H0/H0.5/H1/H2/H3/H4/H6/H10/H24/H36/H48/H72/H96/H120/H144（H means Hour）.In the study of multiple-dose,full PK profiles will be obtained at D1/D8/D15/D21/D28（D means Day）</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response Rate(ORR)</measure>
    <time_frame>each 28 days up to intolerance the toxicity or PD (up to 24 months)</time_frame>
    <description>Percentage of participants with OR based assessment of confirmed complete remission (CR) or confirmed partial remission (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Advanced Cancer</condition>
  <arm_group>
    <arm_group_label>TQ-B3101</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TQ-B3101 QD po and it should be continued until disease progression or intolerable toxicity or patients withdrawal of consent</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TQ-B3101</intervention_name>
    <description>Escalating doses of TQ-B3101 will be administered orally on a continuous dosing schedule. Doses to be evaluated will range from 100 mg to 500 mg/day administered either once or twice a day. A treatment cycle is considered to be 28 days .</description>
    <arm_group_label>TQ-B3101</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histological documentation of Advanced solid tumors

          -  Lack of the standard treatment or treatment failure

          -  18-70years,ECOG PS:0-1,Life expectancy of more than 3 months

          -  Main organs function is normal

          -  Women of childbearing potential should agree to use and utilize an adequate method of
             contraception (such as intrauterine device，contraceptive and condom) throughout
             treatment and for at least 6 months after study is stopped；the result of serum or
             urine pregnancy test should be negative within 7 days prior to study enrollment，and
             the patients required to be non-lactating；Man participants should agree to use and
             utilize an adequate method of contraception throughout treatment and for at least 6
             months after study is stopped

          -  Patients should participate in the study voluntarily and sign informed consent

        Exclusion Criteria:

          -  Patients with treatment failure by ALK/ROS1 inhibitor

          -  Patients with anti-teratment,radiotherapy or surgery within 4 weeks

          -  Patients participated in other anticancer drug clinical trials within 4 weeks or
             ALK/ROS1 inhibitor within 1 week

          -  Blood pressure unable to be controlled(systolic pressure&gt;140 mmHg，diastolic
             pressure&gt;90 mmHg). Patients with Grade 1 or higher myocardial ischemia, myocardial
             infarction or malignant arrhythmias(including QT≥470ms)

          -  Patients with non-healing wounds or fractures

          -  Patients with drug abuse history and unable to get rid of or Patients with mental
             disorders

          -  History of immunodeficiency

          -  Patients with concomitant diseases which could seriously endanger their own safety or
             could affect completion of the study according to investigators' judgment
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Hongming Pan, Doctor</last_name>
    <phone>0571-86960497</phone>
    <email>panhongming63@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sir Run Run Shaw Hospital,School of Medicine, Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310016</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hongming Pan, Doctor</last_name>
      <email>panhongming63@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>January 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 10, 2017</study_first_submitted>
  <study_first_submitted_qc>January 10, 2017</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 12, 2017</study_first_posted>
  <last_update_submitted>September 15, 2017</last_update_submitted>
  <last_update_submitted_qc>September 15, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">September 18, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

